Impacts of tumor microenvironment during neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma

被引:2
|
作者
Sugawara, Kotaro [1 ]
Fukuda, Takashi [1 ]
Murakami, Chiaki [2 ,3 ]
Oka, Daiji [1 ]
Yoshii, Takako [4 ]
Amori, Gulanbar [2 ,5 ,6 ]
Ishibashi, Kumiko [2 ]
Kobayashi, Yasuhito [2 ]
Hara, Hiroki [4 ]
Kanda, Hiroaki [2 ]
Motoi, Noriko [2 ,7 ]
机构
[1] Saitama Canc Ctr, Dept Gastroenterol Surg, Saitama, Japan
[2] Saitama Canc Ctr, Dept Pathol, 780 Komuro, Ina, Saitama 3620806, Japan
[3] Saitama Med Univ, Saitama Med Ctr, Dept Pathol, Saitama, Japan
[4] Saitama Canc Ctr, Dept Gastroenterol, Saitama, Japan
[5] Japanese Fdn Canc Res, Canc Inst, Div Pathol, Tokyo, Japan
[6] Japanese Fdn Canc Res, Canc Inst Hosp JFCR, Dept Pathol, Tokyo, Japan
[7] Saitama Canc Ctr, Ctr Canc Genom Med, Saitama, Japan
关键词
esophageal squamous cell carcinoma; immune checkpoint inhibitor; neoadjuvant chemotherapy; surgery; tumor microenvironment; INFILTRATING LYMPHOCYTES; CANCER; EXPRESSION; SURVIVAL; THERAPY;
D O I
10.1111/cas.16203
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
With the advent of immune checkpoint inhibitors (ICIs), a better understanding of tumor microenvironment (TME) is becoming crucial in managing esophageal squamous cell carcinoma (ESCC) patients. We investigated the survival impact of TME status and changes in patients with ESCC who underwent neoadjuvant chemotherapy (NAC) followed by surgery (n = 264). We examined immunohistochemical status (CD4+, CD8+, CD20+, Foxp3+, HLA class-1+, CD204+, and programmed death ligand-1 [PD-L1+]) on 264 pre-NAC and 204 paired post-NAC specimens. Patients were classified by their pre- and post-NAC immune cell status and their changes following NAC. Our findings showed that pre-NAC TME status was not significantly associated with survival outcomes. In contrast, post-NAC TME status, such as low level of T cells, CD4+ T cells, and high PD-L1 combined positive score (CPS), were significantly associated with poor overall survival (OS). Notably, TME changes through NAC exerted significant survival impacts; patients with consistently low levels of T cells, low levels of CD4+ T cells, or high levels of PD-L1 (CPS) had very poor OS (3-year OS: 35.5%, 40.2%, and 33.3%, respectively). Tumor microenvironment changes of consistently low T cells, low CD4+ T cells, and high PD-L1 were independent predictors of poor OS in multivariate Cox hazards analyses, while factors indicating post-NAC status (T cells, CD4+, and PD-L1 [CPS]) alone were not. Therefore, we suggest that the consistently low T/high PD-L1 group could benefit from additional therapies, such as ICIs, and the importance of stratification by the TME, which has recently been recognized. Tumor microenvironment after neoadjuvant chemotherapy (NAC), such as low T cells, low CD4+ cells, or high programmed death ligand-1 [PD-L1], were significantly associated with poor survival in patients with esophageal squamous cell carcinoma. Importantly, immune cell changes following NAC, such as consistently low T cells, consistently low CD4+ cells, or persistently high PD-L1, were independent predictors for poor survival.image
引用
收藏
页码:2819 / 2830
页数:12
相关论文
共 50 条
  • [41] Predicting tumor response and prognosis to neoadjuvant chemotherapy in esophageal squamous cell carcinoma patients using PERCIST: a multicenter study in Japan
    Hayato Kaida
    Kazuhiro Kitajima
    Masatoyo Nakajo
    Mana Ishibashi
    Tomoyuki Matsunaga
    Ryogo Minamimoto
    Kenji Hirata
    Koya Nakatani
    Ao Hung
    Satoshi Hattori
    Takushi Yasuda
    Kazunari Ishii
    [J]. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 3666 - 3682
  • [42] Predicting tumor response and prognosis to neoadjuvant chemotherapy in esophageal squamous cell carcinoma patients using PERCIST: a multicenter study in Japan
    Kaida, Hayato
    Kitajima, Kazuhiro
    Nakajo, Masatoyo
    Ishibashi, Mana
    Matsunaga, Tomoyuki
    Minamimoto, Ryogo
    Hirata, Kenji
    Nakatani, Koya
    Hung, Ao
    Hattori, Satoshi
    Yasuda, Takushi
    Ishii, Kazunari
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (11) : 3666 - 3682
  • [43] Evaluation of tumor immune microenvironment after neoadjuvant immunotherapy in patients with esophageal squamous cell carcinoma (ESCC): Towards a prediction for recurrence risk
    Liu, Zhichao
    Yu, Boyao
    Yang, Yuxin
    Qi, Cong
    Yuan, Chang
    Yang, Yang
    Wei, Jinzhi
    Chen, Sidong
    Wang, Yang
    Li, Zhigang
    [J]. CANCER RESEARCH, 2023, 84 (06)
  • [44] The Immunological Impact of Chemotherapy on the Tumor Microenvironment of Oral Squamous Cell Carcinoma
    Takakura, Hiroaki
    Domae, Shohei
    Ono, Toshiro
    Sasaki, Akira
    [J]. ACTA MEDICA OKAYAMA, 2017, 71 (03) : 219 - 226
  • [45] NEOADJUVANT CHEMOTHERAPY-PLUS-RADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS-CELL CARCINOMA
    HELLBARDT, A
    AAPRO, M
    SAPPINO, AP
    MIRIMANOFF, RO
    MEGEVAND, R
    [J]. HELVETICA CHIRURGICA ACTA, 1989, 56 (04) : 435 - 441
  • [46] Evaluating Neoadjuvant Chemotherapy for Lower Esophageal Squamous Cell Carcinoma by Measuring Esophageal Wall Thickness
    Sato, H. I. R. O. M. I. C. H. I.
    Nishikawa, K. A. Z. U. H. I. R. O.
    Hamakawa, T. A. K. U. Y. A.
    Kusunoki, C. H. I. K. A. K. O.
    Miyake, M. A. S. A. K. A. Z. U.
    Miyamoto, A. T. S. U. S. H., I
    Kato, T. A. K. E. S. H., I
    Mano, M. A. S. A. Y. U. K., I
    Takami, K. O. J., I
    Hirao, M. O. T. O. H. I. R. O.
    [J]. ANTICANCER RESEARCH, 2022, 42 (11) : 5655 - 5662
  • [47] Impact of Tumor Size on Survival Outcome in Esophageal Squamous Cell Carcinoma After Esophagectomy Following Neoadjuvant Chemotherapy
    Koterazawa, Yasufumi
    Oshikiri, Taro
    Goto, Hironobu
    Kato, Takashi
    Sawada, Ryuichiro
    Harada, Hitoshi
    Urakawa, Naoki
    Hasegawa, Hiroshi
    Kanaji, Shingo
    Yamashita, Kimihiro
    Matsuda, Takeru
    Kakeji, Yoshihiro
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (04) : 2482 - 2489
  • [48] Impact of Tumor Size on Survival Outcome in Esophageal Squamous Cell Carcinoma After Esophagectomy Following Neoadjuvant Chemotherapy
    Yasufumi Koterazawa
    Taro Oshikiri
    Hironobu Goto
    Takashi Kato
    Ryuichiro Sawada
    Hitoshi Harada
    Naoki Urakawa
    Hiroshi Hasegawa
    Shingo Kanaji
    Kimihiro Yamashita
    Takeru Matsuda
    Yoshihiro Kakeji
    [J]. Annals of Surgical Oncology, 2024, 31 : 2482 - 2489
  • [49] The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
    Lv, Huilai
    Huang, Chao
    Li, Jiachen
    Zhang, Fan
    Gai, Chunyue
    Liu, Zhao
    Xu, Shi
    Wang, Mingbo
    Li, Zhenhua
    Tian, Ziqiang
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 13
  • [50] The Role of Adjuvant Chemotherapy after Neoadjuvant Chemoradiotherapy Followed by Surgery in Patients with Esophageal Squamous Cell Carcinoma
    Park, Seong Yong
    Kim, Hong Kwan
    Jeon, Yeong Jeong
    Lee, Junghee
    Cho, Jong Ho
    Choi, Yong Soo
    Shim, Young Mog
    II Zo, Jae
    [J]. CANCER RESEARCH AND TREATMENT, 2023, 55 (04): : 1231 - 1239